State Health Plan Legal Victory Fuels Bus Tour
Topics Related to SHP Press Release
North Carolina Hospitals Used the Federal Safety-Net 340B Drug Pricing Program to Enrich Themselves Rather Than to Serve Vulnerable Communities
Treasurer and Team are Weighing Supreme Court Appeal
Seek Help to Lower Costs of Expensive Weight-Loss Drugs
Treasurer Folwell Applauds Court Ruling
Today, the federal Food and Drug Administration (FDA) approved the first GIP/GLP-1 called “Zepbound” for the purpose of weight loss. The drug is manufactured by Eli Lily and contains tirzepatide, the same active ingredient already present in an existing medication called Mounjaro. The State Health Plan (SHP) added Mounjaro to its approved list of pharmaceuticals for the purpose of treating diabetes effective Jan. 1, 2024.
UNC Health and ECU Leave State Employees and Taxpayers with a $1 Billion Bill and Threaten the Tax-Exempt Status of the Pension Plan
High Medication Cost Leads State Health Plan to Consider Removing GLP-1 Drugs from Coverage
New Program Partners with CVS Caremark, GoodRx, to Target Some High-Cost Prescriptions, Lowering Out-of-Pocket Costs for Members
North Carolina Hospitals Charge Families Huge Price Markups for Common Shoppable Services, Hide Prices from Patients